| Walmart Pharmacy 10-8279 | |
| 2201 Ross Osage St, Amarillo, Texas 79103 | |
| (806) 734-0622 |
| Name | Walmart Pharmacy 10-8279 |
|---|---|
| Organization Name | Sams East Inc |
| Location | 2201 Ross Osage St, Amarillo, Texas 79103 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (806) 734-0622 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
The new test, based on research carried out at the Max Planck Institute of Psychiatry, should help doctors to decrease the risk of suicidality in patients treated with antidepressants who show certain gene markers. Sundance is completing a new round of funding to extend the initial validation results reported by the Institute. The company plans to launch the test immediately as a laboratory developed test. In addition, clinical studies in support of a U.S. Food and Drug Administration submission for market clearance, CE marking and reimbursement will be initiated. Sundance expects to submit its application to the agencies within 18 months.
Celsis International Ltd. announced today that Celsis In Vitro, Inc. has reached a settlement agreement with XenoTech, LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in a patent infringement lawsuit filed by Celsis IVT on February 2, 2010.
Findings from an interim analysis of a new study comparing the hemoglobin response rates of Epoetin alfa and darbepoetin alfa in the treatment of chemotherapy-related anemia were published in the November 15, 2004 issue of the Medical Journal 'Blood' as part of the American Society of Hematology 46th Annual Meeting and Exposition.
The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) awarded a $51 million contract to Emergent BioSolutions, Inc., of Rockville, Md., for the development of a new anthrax vaccine using the protective antigen (rPA) to stimulate a protective immune response that neutralizes the anthrax toxins.
Computational modeling has provided new insights into the heart's vascular system, a complex and mechanically demanding system that remains poorly understood.
› Verified 3 days ago
| NPI Number | 1730106899 |
| Organization Name | SAMS EAST INC |
| Doing Business As | SAMS PHARMACY |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 2201 Ross Osage St, Amarillo, TX 79103 |
| Phone Number | 806-374-0622 |
News Archive
The new test, based on research carried out at the Max Planck Institute of Psychiatry, should help doctors to decrease the risk of suicidality in patients treated with antidepressants who show certain gene markers. Sundance is completing a new round of funding to extend the initial validation results reported by the Institute. The company plans to launch the test immediately as a laboratory developed test. In addition, clinical studies in support of a U.S. Food and Drug Administration submission for market clearance, CE marking and reimbursement will be initiated. Sundance expects to submit its application to the agencies within 18 months.
Celsis International Ltd. announced today that Celsis In Vitro, Inc. has reached a settlement agreement with XenoTech, LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in a patent infringement lawsuit filed by Celsis IVT on February 2, 2010.
Findings from an interim analysis of a new study comparing the hemoglobin response rates of Epoetin alfa and darbepoetin alfa in the treatment of chemotherapy-related anemia were published in the November 15, 2004 issue of the Medical Journal 'Blood' as part of the American Society of Hematology 46th Annual Meeting and Exposition.
The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) awarded a $51 million contract to Emergent BioSolutions, Inc., of Rockville, Md., for the development of a new anthrax vaccine using the protective antigen (rPA) to stimulate a protective immune response that neutralizes the anthrax toxins.
Computational modeling has provided new insights into the heart's vascular system, a complex and mechanically demanding system that remains poorly understood.
› Verified 3 days ago
News Archive
The new test, based on research carried out at the Max Planck Institute of Psychiatry, should help doctors to decrease the risk of suicidality in patients treated with antidepressants who show certain gene markers. Sundance is completing a new round of funding to extend the initial validation results reported by the Institute. The company plans to launch the test immediately as a laboratory developed test. In addition, clinical studies in support of a U.S. Food and Drug Administration submission for market clearance, CE marking and reimbursement will be initiated. Sundance expects to submit its application to the agencies within 18 months.
Celsis International Ltd. announced today that Celsis In Vitro, Inc. has reached a settlement agreement with XenoTech, LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in a patent infringement lawsuit filed by Celsis IVT on February 2, 2010.
Findings from an interim analysis of a new study comparing the hemoglobin response rates of Epoetin alfa and darbepoetin alfa in the treatment of chemotherapy-related anemia were published in the November 15, 2004 issue of the Medical Journal 'Blood' as part of the American Society of Hematology 46th Annual Meeting and Exposition.
The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) awarded a $51 million contract to Emergent BioSolutions, Inc., of Rockville, Md., for the development of a new anthrax vaccine using the protective antigen (rPA) to stimulate a protective immune response that neutralizes the anthrax toxins.
Computational modeling has provided new insights into the heart's vascular system, a complex and mechanically demanding system that remains poorly understood.
› Verified 3 days ago
Advanced Vital Care Type: Medicare Supplier Location: 1901 Medi Park Dr, Amarillo, Texas 79106 Phone: (806) 242-2272 | |
Amarillo Diagnostic Clinic Rx Inc Type: Long Term Care Pharmacy Location: 6700 Sw 9th Ave, Amarillo, Texas 79106 Phone: (806) 358-0331 | |
Amarillo I Care, Pc Type: Medicare Supplier Location: 3501 S Soncy Rd, Amarillo, Texas 79119 Phone: (806) 352-3157 | |
Britkare Home Medical Type: DME Supplier - Customized Equipment Location: 2112 S Coulter St, Amarillo, Texas 79106 Phone: (806) 350-2445 | |
Britkare Home Medical Of Texas Ltd Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1800 S Coulter St, Amarillo, Texas 79106 Phone: (806) 351-2500 |